Pharmaceuticals, Biotechnology and Life Sciences
Sanofi and GSK today announced teaming up to work on a vaccine for COVID-19, as Sanofi will contribute its S-protein COVID-19 antigen, and GSK contributing pandemic adjuvant technology.
Sanofi and Regeneron’s phase 3 clinical trial results announced Friday show Dupixent (dupilumab) combined with standard-of-care topical corticosteroids (TCS) in children aged 6-11 years with uncontrolled severe atopic dermatitis significantly improved disease signs, symptoms and health-related quality of life.
European Commission has approved a third indication for Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is also approved for moderate-to-severe atopic dermatitis and severe asthma.
Eligible PEA PME) (Paris:ALCOR), a French company specializing in the development and manufacturing of medical devices and smart drug delivery systems, announces that they have entered into an exclusive negotiation with SANOFI, a worldwide leader within the pharmaceutical industry, aimed at introducing their Mallya connected device into SANOFI’s integrated diabetes care platform.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has nodded for extension for Dupixent, following USFDA’s approval for nasal polyposis, enabling its approval in the European Union (EU) to also include adolescents 12 to 17 years of age with moderate-to-severe AD who are candidates for systemic therapy.
Regeneron Pharmaceuticals and Sanofi got the approval from the FDA for Dupixent for certain combinations to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Sanofi’s MenQuadfi Meningococcal Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis will be reviewed for BLA by the FDA, expecting to reach the decision on April 25, 2020.
DUBLIN–(BUSINESS WIRE)–The “Real-World Data Capabilities: Benchmarking Pharma Companies (2019)” report has been added to ResearchAndMarkets.com’s offering. Are you fully and…
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Osteoarthritis” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Osteoarthritis market,…
Sanofi and Regeneron Pharmaceuticals said Friday a Phase 2 proof-of-concept trial evaluating the investigational IL-33 antibody REGN3500 (SAR440340) met the primary endpoint of improvement in loss of asthma control when comparing REGN3500 monotherapy to placebo.